Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose aspirin to enhance fecal immunochemical detection of advanced colorectal neoplasms
2019-003770-85Phase 3Terminated
- Sponsor
- German Cancer Research Center
- Start
- Jun 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of aspirin in advanced colorectal neoplasm, colorectal cancer (CRC), Advanced adenoma (AA) and 1 more (2 arms), sponsored by German Cancer Research Center. Primary endpoint: Sensitivity of fecal immunochemical testing after 3 days of low-dose acetylsalicylic acid. Started Jun 2020; status: terminated.
02
Drugs
aspirin
03
Conditions
advanced colorectal neoplasmcolorectal cancer (CRC)Advanced adenoma (AA)Sessile Serrated Lesion (SSL)
Beyond the preview
Go deeper on 2019-003770-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003770-85.